Stratification of cardiovascular risk in patients with chronic obstructive pulmonary disease


DOI: https://dx.doi.org/10.18565/therapy.2020.5.69-77

Dolbin S.S., Adasheva T.V., Samorukova E.I., Malyavin A.G., Li V.V., Vysotskaya N.V., Zadionchenko V.S.

1) Central polyclinic, Moscow; 2) A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia
The aim of the study was to estimate cardiovascular risk in patients with chronic obstructive pulmonary disease (COPD) using standard scales and methods.
Material and methods. In the process of the study, a group of patients with COPD was formed. It included 41 person with diagnosis confirmed according to the GOLD 2019 recommendations. The control group consisted of patients comparable to the main group in terms of demographic characteristics and smoking status. All participants of the study underwent an estimation of cardiovascular risk (CVR) according to the SCORE scale, Reynolds scale, calculation of the Charlson comorbidity index, determination of highly sensitive C-reactive protein (hs-CRP), glomerular filtration rate, and lipid spectrum indexes examination.
Results. In all patients of the COPD group, CVR was stratified as high and very high. An increase in hf-CRP, CVR (SCORE and Reynolds scales) has been shown as COPD was progressing. Correlations were found between the severity of COPD and the incidence of arterial hypertension (r=0,723; p <0.05) and the level of hf-CRP (0,518; p <0.05). In all patients of the COPD group, in accordance with CVR stratification, indications for lipid-lowering therapy prescribing were identified. It was prescribed in 63% of cases. None of the patients achieved the target level of low-density lipoprotein cholesterol (LDL-C) during primary and secondary prevention.
Conclusion. COPD is a status of high cardiovascular risk, therefore it is necessary to include this disease in CVR stratification scales. All patients with COPD without manifesting cardiovascular diseases need CVR estimation using routine scales with the development of individual preventive measures.
Keywords: chronic obstructive pulmonary disease, cardiovascular risk, comorbidity, lipid-lowering therapy
Read entire article

Literature


  1. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med 2017; 5(9): 691–706. doi: 10.1016/S2213-2600(17)30293-X.

  2. https://www.who.int/ru/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(COPD) (date of access – 01.09.2020).

  3. Lozano R., Naghavi M., Foreman K. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2095–128. doi: 10.1016/S0140-6736(12)61728-0.

  4. Никитин В.А., Васильева Л.В., Толстых Е.М., Ноговицына А.С. Роль системного воспаления в развитии коморбидности при хронической обструктивной болезни легких. Туберкулез и болезни легких. 2017; 6: 61–66. [Nikitin V.A., Vasilieva L.V., Tolstykh E.M., Nogovitsyna A.S. The role of systemic inflammation in the development of comorbidity in chronic obstructive pulmonary disease. Tuberkulyoz i bolezni lyogkikh. 2017; 6: 61–66 (In Russ.)]. doi: 10.21292/2075-1230-2017-95-6-61-66.

  5. Vanfleteren L.E.G.W., Spruit M.A., Groenen M. et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med. 2013; 187(7): 728–35. doi: 10.1164/rccm.201209-1665OC.

  6. van Durme Y.M., Verhamme K.M., Stijnen T. et al. Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam study. Chest. 2009; 135(2): 368–77. doi: 10.1378/chest.08-0684.

  7. Hill K., Goldstein R.S., Guyatt G.H. et al. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ. 2010; 182(7): 673–78. doi: 10.1503/cmaj.091784.

  8. Echave J.M., Martin-Escudero J.C., Anton E. et al. Comorbidity in COPD in Spain. Am J Respir Crit Care Med. 2009; 179: А1462. doi: 10.1164/ajrccm-conference.2009.179.1_MeetingAbstracts.A1462.

  9. Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular disease? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003; 107(11): 1514–19. doi: 10.1161/01.cir.0000056767.69054.b3.

  10. Finkelstein J., Cha E., Scharf S.M. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis. 2009; 4: 337–49. doi: 10.2147/copd.s6400.

  11. Mazza A., Zamboni S., Rubello D. et al. Chronic obstructive pulmonary disease and cardiovascular mortality in elderly subjects from general population. Blood Press. 2010; 19(2): 67–74. doi: 10.3109/08037050903464642.

  12. Chen W., Thomas J., Sadatsafavi M., FitzGerald J.M. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med 2015; 3(8): 631–39. doi: 10.1016/S2213-2600(15)00241-6.

  13. Onishi K. Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease. J Cardiol. 2017; 70(2): 128–34. doi: 10.1016/j.jjcc.2017.03.001.

  14. Малявин А.Г., Мартынов А.И., Адашева Т.В. с соавт. Национальные клинические рекомендации. Диагностика и лечение пациентов с хронической обструктивной болезнью легких и артериальной гипертензией. Терапия. 2018; 5 (приложение): 3–58. [Malyavin A.G., Martynov A.I., Adasheva T.V. et al. National clinical guidelines. Diagnostics and treatment of patients with chronic obstructive pulmonary disease and arterial hypertension. Therapy. 2018; 5 (Suppl): 3–58 (In Russ.)].

  15. Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009; 33(5): 1165–85. doi: 10.1183/09031936.00128008.

  16. Young R., Hopkins R., Eaton T. Comorbidities in COPD. Eur Respir J. 2009; 34(6): 1497–98. doi: 10.1183/09031936.00117209.

  17. van Eeden S., Leipsic J., Paul Man S.F. et al. The relationship between lung inflammation and cardiovascular disease. Am J Respir Crit Care Med. 2012; 186(1): 11–16. doi: 10.1164/rccm.201203-0455PP.

  18. Young R.P., Hopkins R., Eaton T.E. Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev. 2009; 18(114): 222–32. doi: 10.1183/09059180.00005309.

  19. Долбин С.С., Адашева Т.В., Задионченко В.С. с соавт. Анализ распространенности и совершенствование методологии выявления хронической обструктивной болезни легких в амбулаторно-поликлинической практике. Терапия. 2019; 5: 45–52. [Dolbin S.S., Adasheva T.V., Zadionchenko V.S. et al. Analysis of the prevalence and improvement of the methodology for copd identification in outpatientpolyclinic practice. Therapy. 2019; 5: 45–52 (In Russ.)]. doi: 10.18565/therapy.2019.5.45-52.

  20. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019. Available at: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf Accessed January 24, 2019 (date of access – 01.09.2020).

  21. Айсанов З.Р., Авдеев С.Н., Архипов В.В. с соавт. Национальные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких: алгоритм принятия клинических решений. Пульмонология. 2017; 1: 13–20. [Aisanov Z.R., Avdeev S.N., Arkhipov V.V. National clinical guidelines on diagnosis and treatment of chronic obstructive pulmonary disease: a clinical decision-making algorithm. Pul'monologiya. 2017; 1: 13–20 (In Russ.)]. doi: 10.18093/0869-0189-2017-27-1-13-20.

  22. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018; 6: 7–122. [Cardiovascular prevention 2017. Russian national guidelines. Rossiysky kardiologichesky zhurnal. 2018; 6: 7–122 (In Russ.)]. doi: 10.15829/1560-4071-2018-6-7-122.

  23. Charlson M.E., Pompei P., Ales K.L. et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987; 40(5): 373–83. doi: 10.1016/0021-9681(87)90171-8.

  24. Miller J., Edwards L.D., Agusti A. et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013; 107(9): 1376–84. doi: 10.1016/j.rmed.2013.05.001.

  25. Кочетова Е.В. Комплексная оценка больных хронической обструктивной болезнью легких с помощью многокомпонентного индекса ADO и индекса коморбидности Charlson. Медицинский совет. 2018; 12: 182–184. [Kochetova E.V. Comprehensive assessment of patients with chronic obstructive pulmonary disease by means of multicomponent ADO index and Charlson comorbidity index. Meditsinsky sovet. 2018; 12: 182–184 (In Russ.)]. doi: 10.21518/2079-701X-2018-12-182-184.

  26. Рекомендации ЕОК/ЕОА по диагностике и лечению дислипидемий 2016. Российский кардиологический журнал. 2017, 5: 7–77. [2016 ESC/EAS guidelines for the management of dyslipidaemias. Rossiysky kardiologichesky zhurnal. 2017, 5: 7–77 (In Russ.)]. doi: 10.15829/1560-4071-2017-5-7-77.


About the Autors

Sergey S. Dolbin, district physician of Central polyclinic. Address: 107031, Moscow, 5 Varsonofievsky Lane. E-mail: sdolbin@yandex.ru
Tatyana V. Adasheva, MD, professor, professor of the Department of polyclinic therapy of A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 129110, Moscow, 61/2 Shchepkina Str., building 9. Tel.: +7 (903) 629-46-07. E-mail: adashtv@mail.ru. ORCID: 0000-0002-3763-8994
Elena I. Samorukova, PhD, senior laboratory assistant of the Department of polyclinic therapy of A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: Moscow, 20/1 Delegatskaya Str. E-mail: wlrad@bk.ru. ORCID: 0000-0002-8912-1348
Andrey G. Malyavin, MD, professor, professor of the Department of phthisiology and pulmonology of the faculty of medicine of A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str. E-mail: maliavin@mail.ru
Vera V. Li, MD, professor of the Department of polyclinic therapy of A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str. E-mail: vera0212@yandex.ru
Vladimir S. Zadionchenko, MD, professor, professor of the Department of polyclinic therapy of A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str. E-mail: z7vladimir@bk.ru. ORCID: 0000-0003-2377-5266
Nina V. Vysotskaya, senior laboratory assistant of the Department of polyclinic therapy of A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str.

Back to Content

Бионика Медиа